Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Joris van de Haar"'
Autor:
Lindsay V. M. Leek, Jessica C. L. Notohardjo, Karlijn de Joode, Eline L. Velker, John B. A. G. Haanen, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Jan Willem B. de Groot, Ellen Kapiteijn, Franchette W. P. J. van den Berkmortel, Hans M. Westgeest, Tanja D. de Gruijl, Valesca P. Retel, Edwin Cuppen, Astrid A. M. van der Veldt, Mariette Labots, Emile E. Voest, Joris van de Haar, Alfons J. M. van den Eertwegh
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract We evaluated the prognostic value of hypoalbuminemia in context of various biomarkers at baseline, including clinical, genomic, transcriptomic, and blood-based markers, in patients with metastatic melanoma treated with anti-PD-1 monotherapy
Externí odkaz:
https://doaj.org/article/0b86698c5e3b43c28f9ef4dd875f5025
Autor:
Krijn K. Dijkstra, José G. van den Berg, Fleur Weeber, Joris van de Haar, Arno Velds, Sovann Kaing, Dennis D. G. C. Peters, Ferry A. L. M. Eskens, Derk-Jan A. de Groot, Margot E. T. Tesselaar, Emile E. Voest
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a poorly understood disease with limited treatment options. A better understanding of this disease would greatly benefit from the availability of representative preclinical models. Here, we
Externí odkaz:
https://doaj.org/article/737cc6a2352e4ea98121176d9873021f
Publikováno v:
ESMO Open, Vol 4, Iss 2 (2019)
Externí odkaz:
https://doaj.org/article/01d3cc6c292c4196add7d3d66a844a3f
Publikováno v:
ESMO Open, Vol 4, Iss 2 (2019)
Externí odkaz:
https://doaj.org/article/2a59435ed918458481b2a54bf2d910ba
Publikováno v:
Nature Reviews Clinical Oncology. 20:305-317
Autor:
Joris van de Haar, Xuhui Ma, Salo N. Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, Nicoletta Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Maria Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F. A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri
Publikováno v:
Nature Medicine
Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome analysis of 37 patients with metastatic colorectal cancer (mCRC) treated
Autor:
Natasja L. de Vries, Joris van de Haar, Vivien Veninga, Myriam Chalabi, Marieke E. Ijsselsteijn, Manon van der Ploeg, Jitske van den Bulk, Dina Ruano, Jose G. van den Berg, John B. Haanen, Laurien J. Zeverijn, Birgit S. Geurts, Gijs F. de Wit, Thomas W. Battaglia, Hans Gelderblom, Henk M. W. Verheul, Ton N. Schumacher, Lodewyk F. A. Wessels, Frits Koning, Noel F. C. C. de Miranda, Emile E. Voest
Publikováno v:
Nature, 613(7945), 743-750. Nature Publishing Group
Nature: international weekly journal of science, 613(7945)
Nature: international weekly journal of science, 613(7945)
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB)1,2. Here, in contrast to other cancer types3–5, we observed that 20 ou
Autor:
Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D.R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V. Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T.A. van der Graaf, Carla M.L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest
Publikováno v:
Clinical Cancer Research, 28(7), 1402-1411. American Association for Cancer Research Inc.
Clinical Cancer Research, 28(7), 1402-1411. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 28, 1402-1411
Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, Zeverijn, L J, van der Velden, D L, van de Haar, J, Roepman, P, de Leng, W J, Jansen, A M L, van Werkhoven, E, van der Noort, V, Huitema, A D R, Gort, E H, de Groot, J W B, Kerver, E D, de Groot, D J, Erdkamp, F, Beerepoot, L V, Hendriks, M P, Smit, E F, van der Graaf, W T A, van Herpen, C M L, Labots, M, Hoeben, A, Morreau, H, Lolkema, M P, Cuppen, E, Gelderblom, H, Verheul, H M W & Voest, E E 2022, ' Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment ', Clinical Cancer Research, vol. 28, no. 7, pp. 1402-1411 . https://doi.org/10.1158/1078-0432.CCR-21-3752
Clinical cancer research, 28(7), 1402-1411. American Association for Cancer Research Inc.
Clinical Cancer Research, 28, 7, pp. 1402-1411
Clinical Cancer Research, 28(7), 1402-1411. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 28, 1402-1411
Hoes, L R, van Berge Henegouwen, J M, van der Wijngaart, H, Zeverijn, L J, van der Velden, D L, van de Haar, J, Roepman, P, de Leng, W J, Jansen, A M L, van Werkhoven, E, van der Noort, V, Huitema, A D R, Gort, E H, de Groot, J W B, Kerver, E D, de Groot, D J, Erdkamp, F, Beerepoot, L V, Hendriks, M P, Smit, E F, van der Graaf, W T A, van Herpen, C M L, Labots, M, Hoeben, A, Morreau, H, Lolkema, M P, Cuppen, E, Gelderblom, H, Verheul, H M W & Voest, E E 2022, ' Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment ', Clinical Cancer Research, vol. 28, no. 7, pp. 1402-1411 . https://doi.org/10.1158/1078-0432.CCR-21-3752
Clinical cancer research, 28(7), 1402-1411. American Association for Cancer Research Inc.
Clinical Cancer Research, 28, 7, pp. 1402-1411
Purpose: Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We hypothesized that patients with rare cancer benefit fro
Autor:
Emile E. Voest, Henk M.W. Verheul, Hans Gelderblom, Edwin Cuppen, Martijn P. Lolkema, Hans Morreau, Ann Hoeben, Mariette Labots, Carla M.L. van Herpen, Winette T.A. van der Graaf, Egbert F. Smit, Mathijs P. Hendriks, Laurens V. Beerepoot, Frans Erdkamp, Derk Jan de Groot, Emile D. Kerver, Jan Willem B. de Groot, Eelke H. Gort, Alwin D.R. Huitema, Vincent van der Noort, Erik van Werkhoven, Anne M.L. Jansen, Wendy J. de Leng, Paul Roepman, Joris van de Haar, Daphne L. van der Velden, Laurien J. Zeverijn, Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, Louisa R. Hoes
Supplementary Figure from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::142be478802724901bf5b4aba218bf7c
https://doi.org/10.1158/1078-0432.22487285.v1
https://doi.org/10.1158/1078-0432.22487285.v1
Autor:
Emile E. Voest, Henk M.W. Verheul, Hans Gelderblom, Edwin Cuppen, Martijn P. Lolkema, Hans Morreau, Ann Hoeben, Mariette Labots, Carla M.L. van Herpen, Winette T.A. van der Graaf, Egbert F. Smit, Mathijs P. Hendriks, Laurens V. Beerepoot, Frans Erdkamp, Derk Jan de Groot, Emile D. Kerver, Jan Willem B. de Groot, Eelke H. Gort, Alwin D.R. Huitema, Vincent van der Noort, Erik van Werkhoven, Anne M.L. Jansen, Wendy J. de Leng, Paul Roepman, Joris van de Haar, Daphne L. van der Velden, Laurien J. Zeverijn, Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, Louisa R. Hoes
Purpose:Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We hypothesized that patients with rare cancer benefit from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20708b4724c2bca311186b13b326a529
https://doi.org/10.1158/1078-0432.c.6532484
https://doi.org/10.1158/1078-0432.c.6532484